Quality of life during sequential hormone replacement therapy -- a placebo-controlled study

Area of Science:

• Reproductive Endocrinology
• Pharmacology
• Clinical Medicine

Background:

• Vasomotor symptoms are a common complaint during menopause.
• Hormone therapy is a primary treatment for menopausal symptoms.
• Sequential estrogen/progestin therapy aims to alleviate symptoms while minimizing risks.

Purpose of the Study:

• To evaluate the efficacy of sequential 17 beta-estradiol and norethindrone acetate (Trisequens) in relieving vasomotor symptoms.
• To compare quality of life, symptom severity, and dropout rates between Trisequens and placebo groups.
• To assess the utility of quality of life rating scales in menopause therapy.

Main Methods:

• A randomized controlled trial involving women aged 40-60 experiencing menopausal symptoms.
• Participants received either Trisequens or a placebo for four consecutive cycles.
• Statistical analysis included analysis of variance and two-tailed tests (P < .05).

Main Results:

• Trisequens significantly reduced the number and severity of daily vasomotor symptoms compared to placebo (1.3 symptoms/day vs. 4.2 symptoms/day).
• Quality of life scores (Kupperman Scale, 3-Factor Green Index, Beck Depression Inventory) showed statistically significant improvements with Trisequens (P < .05).
• The dropout rate was significantly lower in the Trisequens group (12/40) compared to the placebo group (23/42, P = 0.028).

Conclusions:

• Sequential 17 beta-estradiol and norethindrone acetate (Trisequens) is an effective treatment for reducing vasomotor symptoms in menopausal women.
• Trisequens significantly improves quality of life and is well-tolerated, as evidenced by the lower dropout rate.
• Quality of life assessments provide valuable data supporting the use of sequential estrogen/progestin therapy for menopause management.